Identification of ATIC as a Novel Target for Chemoradiosensitization

Journal Article · Mon Jan 15 00:00:00 EST 2018 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2017.08.033· OSTI ID:23100738

Liu, Xiangfei ^[1]; Paila, Uma Devi ^[2]; Teraoka, Sharon N.; Wright, Jocyndra A.; Huang, Xin ^[1]; Quinlan, Aaron R. ^[3]; Gatti, Richard A. ^[4]; Concannon, Patrick ^[1]

---

1. Genetics Institute and Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville (United States)
2. Department of Public Health Sciences, Center for Public Health Genomics, University of Virginia, Charlottesville (United States)
3. Department of Human Genetics, University of Utah, Salt Lake City (United States)
4. Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles (United States)

Mutations in the gene encoding 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), a bifunctional enzyme that catalyzes the final 2 steps of the purine de novo biosynthetic pathway, were identified in a subject referred for radiation sensitivity testing. Functional studies were performed to determine whether ATIC inhibition was radiosensitizing and, if so, to elucidate the mechanism of this effect and determine whether small molecule inhibitors of ATIC could act as effective radiosensitizing agents.

• OSTI ID: 23100738
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 100, Issue 1; Other Information: Copyright (c) 2017 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ENZYMES
MUTATIONS
PURINES
RADIOSENSITIVITY